– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Invitae (NVTA ...
Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...
SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Invitae (NVTA) (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (BBIO), a commercial-stage ...
A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. San Francisco genetic testing firm Invitae succeeded this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback